《新股表现》欧康维视生物(01477.HK)高开1.9倍报43元
欧康维视生物-B(01477.HK)暗盘高开91%报28元获承接,高收43.9元较上市价飙约2倍;该股首挂开报43元,较上市价14.66元,高1.9倍,市前成交1,664万股。
欧康维视是一家内地眼科医药平台公司,致力於识别、开发和商业化同类首创或同类最佳眼科疗法。是次来港上市共发售近1.06亿股,并已引入包括富达基金及贝莱德基金等14名基石投资者,合共认购5,285.35万股;其中10%公开发售获近1,895倍超购,已启动回拨机制占比增至50%,认购一手中签率仅5%;股份以招股范围(13.16-14.66元)上限定价,料集资净额约14.24亿元,主要用於核心产品OT-401和其他候选药物,以及用於根据与市政府所订合作协议收购苏州制造设施等。上市联席保荐人分别为大摩及高盛。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.